PATIENT ACCESS TO ORPHAN MEDICINES IN TURKEY

被引：0
|
作者：
Kockaya, G. [1 ]
Ergin, Oguzhan G. [2 ]
Kurnaz, M. [3 ]
Okcun, S. [3 ]
Talay, D. [4 ]
Gedik, Sar C. [4 ]
Saylan, M. [4 ]
机构：
[1] ECONiX, Ankara, Turkey
[2] 19 Mayis Univ, Samsun, Turkey
[3] ECONiX, Istanbul, Turkey
[4] Hlth Econ & Policy Assoc, Ankara, Turkey
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRO75
引用
下载
收藏
页码：S854 / S855
页数：2
相关论文
共 50 条
  • [21] Orphan medicines' therapeutic profile
    de Barros, Carla Teixeira
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S194 - S195
  • [22] International differences in patient access to ultra-orphan drugs
    Kanters, Tim A.
    Redekop, W. Ken
    Hakkaart, Leona
    HEALTH POLICY AND TECHNOLOGY, 2018, 7 (01) : 57 - 64
  • [23] Patient Access to Medicines for Rare Diseases in European Countries
    Deticek, Andreja
    Locatelli, Igor
    Kos, Mitja
    VALUE IN HEALTH, 2018, 21 (05) : 553 - 560
  • [24] ANALYSIS OF PATIENT ACCESS TO PERSONALIZED ONCOLOGY MEDICINES IN TURKIYE
    Okcun, S.
    Ozturk, F.
    Kockaya, G.
    VALUE IN HEALTH, 2022, 25 (12) : S233 - S233
  • [25] VARIABILITY IN LOCAL UPTAKE AND PATIENT ACCESS TO MEDICINES - IMPLEMENTATION OF SCOTTISH MEDICINES CONSORTIUM GUIDELINES
    White, R.
    Mallinson, M.
    VALUE IN HEALTH, 2013, 16 (03) : A258 - A258
  • [26] UNMET NEED, STRENGTH OF EVIDENCE, AND PRICE: IMPACT ON TIME TO ACCESS FOR ORPHAN MEDICINES IN ENGLAND AND FRANCE
    Fernandes, J.
    Kumar, A.
    Cassidy, C.
    VALUE IN HEALTH, 2020, 23 : S704 - S704
  • [27] Access to medicines for orphan diseases: Experience in the management of a case of Fasciola hepatica in Mumbai, Maharashtra, India
    Thatte, U. M.
    Gogtay, N. J.
    Sridharan, K.
    Oak, S. N.
    NATIONAL MEDICAL JOURNAL OF INDIA, 2012, 25 (04): : 234 - 235
  • [28] Patient-based evidence: its role in decision making on end-of-life, orphan, and ultra-orphan medicines
    Hems, Sharon
    Taylor, Louise
    Jones, Jan
    Holmes, Eileen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
  • [29] Orphan drugs, pediatric medicines in oncology
    De Saunière, A
    EUROCANCER 2002, 2002, : 277 - 278
  • [30] Orphan medicines: a success with a challenging future
    Saint-Raymond, Agnes
    Llinares, Jordi
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (03): : 185 - 187
12345